Zymeworks Inc. Announces Board and Officer Changes

Ticker: ZYME · Form: 8-K · Filed: Feb 18, 2025 · CIK: 1937653

Zymeworks INC. 8-K Filing Summary
FieldDetail
CompanyZymeworks INC. (ZYME)
Form Type8-K
Filed DateFeb 18, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: management-change, board-of-directors, officer-appointments

TL;DR

Zymeworks shakes up its board and exec team, filing new appointments and departures.

AI Summary

Zymeworks Inc. announced on February 17, 2025, a change in its board of directors and executive officers. The filing details the departure of certain directors and officers, the election of new directors, and updates to compensatory arrangements for its officers. The company, incorporated in Delaware, is involved in pharmaceutical preparations.

Why It Matters

Changes in a company's board and executive team can signal shifts in strategy, operational focus, or financial direction, impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Changes in leadership and board composition can introduce uncertainty regarding future strategy and execution.

Key Numbers

Key Players & Entities

FAQ

Who has departed from Zymeworks Inc.'s board or officer positions?

The filing indicates the departure of certain directors and officers, though specific names are not detailed in this excerpt.

Were any new directors elected to Zymeworks Inc.'s board?

Yes, the filing states that new directors have been elected.

What is the primary business of Zymeworks Inc.?

Zymeworks Inc. is in the Pharmaceutical Preparations industry, with SIC code 2834.

When was the earliest event reported in this 8-K filing?

The earliest event reported is dated February 17, 2025.

What is the principal executive office address for Zymeworks Inc.?

The principal executive offices are located at 108 Patriot Drive, Suite A, Middletown, Delaware 19709.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on February 18, 2025 regarding Zymeworks Inc. (ZYME).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing